Exhibit 10.2

 

Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 240-24b-2

 

Statement of Work

 

To the Agreement between RADIUS HEALTH, INC. (“RADIUS”) and LONZA Sales AG dated
16 of October 2007

 

Supplemental analytical services

 

Number

 

RDS-001-SC004

 

 

Product Code/Name

 

RDS-001 Abaloparatide

 

 

Description of the proposed change:

 

Supplemental services requested by Radius:

1)             Manufacturing of an RS solution and supply of 60 vials to Vetter

2)             Additional LC-MS analysis (M-076-RDS-001) and reissue a new CoA
of batch 2AN1.

 

 

 

Price Agreed

 

1.              [*]€

2.              [*]€

 

Total: [*]€

 

 

Radius

 

Name: Naveen Palwai

Signature: /s/ Naveen Palwai

 

Date : 11 Mar 2016

Radius

 

Name:           Wajiha Khan
David Hanley

Signature: /s/ David Hanley

 

Date : 11 Mar 2016

Lonza Sales AG

 

Name : Paul Tastenhoye

Signature : /s/ Paul Tastenhoye

 

Date: 11/03/2016

Lonza Sales AG

 

Name : Frederique Mutterer

Signature : /s/ Frederique Mutterer

 

Date : 11/03/16

 

Additional notes: /

 

--------------------------------------------------------------------------------

[*] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

1

--------------------------------------------------------------------------------

 

Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 240-24b-2

 

Detailed description of the proposed change

 

Activity 1: Manufacturing of an RS solution and supply of 60 vials to Vetter.
Radius to communicate which reference standard is to be used for this liquid
reference solution.

 

Activity 2: Additional LC-MS analysis (M-076-RDS-001) and reissue a new CoA of
batch 2AN1.

 

Timescale

 

Activity 1: By mid-May

 

Activity 2: By March 25th (prior to NDA filing)

 

Price and Terms of Payment

 

1.                  Price

 

·                  Activity 1: [*]€

·                  Activity 2: [*]€

·                  Total price: [*]€

 

2.      Payment

 

100% upon completion

 

oooOOOooo

 

--------------------------------------------------------------------------------

[*] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

 

2

--------------------------------------------------------------------------------